Compare Ascendis Pharma A/S (ASND) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Domino's Pizza, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Domino's Pizza, Inc. trades at $300.01 (market cap $9.96B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.66% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DPZ | |
|---|---|---|
Market Cap | $17.74B | $9.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $485.53 |
52-Week Low | $163.32 | $282.89 |
Enterprise Value | $18.11B | $14.86B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Domino's Pizza (DPZ) trades at $299.46, down 0.47% on the day, near its 52-week low. The stock shows a bearish technical signal with support at $297 and resistance at $304. Fundamentally, revenue grew to $4.94B in 2025 with a net income margin of 11.89%, though recent quarters have seen earnings misses. The company maintains strong profitability but faces headwinds from slowing US sales growth and a CEO transition announced in June 2026.
The outlook is mixed: analyst consensus is bullish with a $380.31 price target, but near-term risks include competitive pressures and macroeconomic challenges. Long-term investors may find value at current levels given the company's market dominance and digital capabilities, though execution under new leadership and sales recovery are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
